摘要
靶向载体研究是近年来肿瘤靶向治疗中的热点。肿瘤靶向载体具有特异性高、毒副作用小的特点,但其无法穿透细胞膜的缺点限制了其对于许多在细胞内起效的抗肿瘤药物的应用。新近发现的细胞穿膜肽(cell-penetrating peptides,CPPs)具有无可比拟的转导活细胞能力。将CPPs和靶向载体联合应用,可综合两者的优点、克服各自缺陷,从而提高肿瘤靶向治疗疗效。依据两者的作用原理和结合方式,可分为自身具有靶向功能的CPPs载体、融合靶向配基的载体、联结CPPs的纳米载体、对肿瘤微环境敏感的CPPs靶向载体和联结其他特殊功能载体的CPPs等5类。不断提高CPPs靶向载体的细胞内化效率和所载药物的释放率,则是将其过度到临床应用必须解决的技术难点。引入CPPs的肿瘤靶向载体的出现,将为抗瘤药物的研发和临床肿瘤治疗提供一个新的手段。
Equipping tumor-targeting carrier with cell-penetrating peptide with high transduction efficacy has become a trend.According to the fusion modes and tumor-targeting mechanisms,cell-penetrating peptides can be divided into five categories：first,self-targeting cell-penetrating peptides;second,fusion carriers made of targeting ligands and cell-penetrating peptides;third,cell-penetrating peptide-modified nano-carrier;fourth,tumor-microenvironment-targeting cell-penetrating peptides;fifth,other special cell-penetrating peptides.Fusion carriers,which can not be effectively released into the cytoplasm after transducted into target cells,can be further modified to increase their efficacy.In all,cell-penetrating peptide introduced into tumor-targeting carrier should provide a new era for anti-tumor pharmacy research and cancer therapy.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
北大核心
2010年第1期104-108,114,共6页
Chinese Journal of Cancer Biotherapy
基金
国家高技术研究发展计划(863计划)(No.2005AA216050、2008A A02Z194)
华侨大学校基金(No.06y0045)~~
关键词
细胞穿膜肽
肿瘤治疗
靶向载体
cell-penetrating peptide
tumor therapy
targeting carrier
